

Ludwig Cancer Research AACR Annual Meeting 2022 Poster Sessions

Session date	Session title	Session type - Location	Poster title	Ludwig location	Presenter/Ludwig PI	Session time (U.S. CST)
4/8/22	Session OPO.CL06.01 - Immunology	Online poster session	5217 - Defining the balance of anti-viral and anti-tumor T cell responses to oncolytic virus therapy using single cell approaches	Ludwig MSK	Bharat Burman/Dmitriy Zamarin, Taha Merghoub, Jedd Wolchok	12:00 PM - 1:00 PM
4/8/22	SESSION OPO.TB06.01 - Tumor Microenvironment	Online poster session	6150 - Potential role of CD47 in T cell exhaustion program	Ludwig MSK	Chien-Huan Weng/Jedd Wolchok, Taha Merghoub	12:00 PM - 1:00 PM
4/8/22	Session OPO.PR01.01 - Preclinical Prevention, Early Detection, and Interception	Online poster session	LB550 - AI predicts risk of pancreatic cancer from disease trajectories using real-world electronic health records (EHRs) from Denmark and the USA	Ludwig Harvard	Bo Yuan/Chris Sander	12:00 PM - 1:00 PM
4/8/22	Session OPO.TB06.01 - Tumor Microenvironment	Online poster session	6147 - Immune population changes in mammary adipose tissue during the development of obesity and their influence on triple negative breast cancer progression	Ludwig Harvard	Shimeng Liu/Myles Brown	12:00 PM - 1:00 PM
4/8/22	Session OPO.MCB06.01 - Cell Cycle	Online poster session	5649 - Bromodomain inhibition reduces CDK6 expression and reverses CDK4/6 inhibitor resistance in ER+ breast cancer	Ludwig Harvard	Renyan Liu/Geoffrey Shapiro	12:00 PM - 1:00 PM
4/8/22	Session OPO.TB07.01 - In Vivo Imaging	Online poster session	LB557 - Multiphoton phosphorescence quenching microscopy reveals kinetics of tumor oxygenation during anti-angiogenesis and angiotensin signaling inhibition	Ludwig Harvard	John Martin/Rakesh Jain	12:00 PM - 1:00 PM
4/10/22	SESSION PO.MCB11.01 - Cellular Stress Responses 1: Hypoxia and Oxidative Stress	Poster session - Section 6	119 / 3 - Pan-cancer analysis of HIF pathways defines a robust molecular signature that reflects tissue and cellular hypoxia in bulk and single-cell RNA-seq analyses	Ludwig Oxford	David Mole/Peter Ratcliffe	1:30 PM - 5:00 PM
4/10/22	Session PO.TB06.06 - Drug Targeting and Treatment Response of the Microenvironment	Poster session - Section 12	250 / 16 - Activating canonical p53 functions in tumor-associated macrophages improves immune checkpoint blockade efficacy	Ludwig MSK	Arbab Ghosh/Taha Merghoub, Jedd Wolchok	1:30 PM - 5:00 PM
4/10/22	Session PO.MCB01.01 - Cell Signaling	Poster session - Section 5	94 / 8 - PRMT5 substrate recruitment as a therapeutic target in CDKN2A/MTAP null cancers	Ludwig Harvard	Kathleen Mulvaney/William Sellers	1:30 PM - 5:00 PM
4/10/22	SESSION MG06 - Meet the Editor-in-Chief of Cancer Research: Chi Van Dang, MD, PhD	Meet and greet - AACR Publications Booth 2101, Exhibit Halls D-H	Interactive discussion with the Editor-in-Chief of Cancer Research about the scope and types of research manuscripts he is seeking to publish in the journal.	Ludwig Cancer Research	Chi Van Dang	4:00 PM - 5:00 PM
4/11/22	Session PO.CL11.06 - Biomarkers Predictive of Therapeutic Benefit 1	Poster session - Section 30	1247 / 19 - Comprehensive molecular profiling to predict first-line immunotherapy outcomes in inoperable esophageal adenocarcinoma	Ludwig Oxford	Thomas Carroll/Xin Lu	9:00 AM - 12:30 PM
4/11/22	SESSION PO.IM01.04 - Molecular Signaling and Metabolic and Epigenetic Regulation in Adaptive Tumor Immunity	Poster session - Section 37	1362 / 21 - Metabolic engineering of CAR-T cells overcomes suppressive adenosine signaling and enhances functionality	Ludwig Stanford	Dorota Klysz/Crystal Mackall	9:00 AM - 12:30 PM
4/11/22	SESSION PO.TB04.05 - Metastatic Cell Plasticity: EMT and Stem Cell	Poster session - Section 12	951 / 3 - BNIP3L/NIX promotes breast cancer growth and metastasis by inducing epithelial-mesenchymal transition	Ludwig Chicago	Damian Berardi/Kay Macleod	9:00 AM - 12:30 PM
4/11/22	Session PO.MCB03.02 - Oncogenes and Tumor Suppressor Genes 2	Poster session - Section 7	862 / 22 - Negative cellular outcomes following acute in vivo Vhl inactivation in mice	Ludwig Oxford	Samvid Kurlekar/Peter Ratcliffe	9:00 AM - 12:30 PM
4/11/22	Session PO.TB01.02 - Genetically Engineered Mouse Models 2	Poster session - Section 11	939 / 9 - A novel lineage-tracing model of Vhldeletion reveals time-dependent cellular changes in the kidney	Ludwig Oxford	Joanna D C C. Lima/Peter Ratcliffe	9:00 AM - 12:30 PM
4/11/22	Session PO.IM02.08 - Immune Mechanisms Invoked by Other Therapies	Poster session - Section 35	1291 / 1 - APR-246 enhances tumor immunogenicity even in the absence of p53	Ludwig MSK	Divya Venkatesh/Jedd Wolchok, Taha Merghoub	9:00 AM - 12:30 PM
4/11/22	Session LBPO.TB02 - Late-Breaking Research: Tumor Biology 2	Late breaking poster session - Section 17	LB056 / 8 - The spatial landscape of progression and immunoediting in primary melanoma at single cell resolution	Ludwig Harvard	Ajit Johnson Nirmal/Sandro Santagata, Peter K. Sorger	9:00 AM - 12:30 PM
4/11/22	Session PO.ET02.03 - Mechanisms of Drug Action 3	Poster session - Section 24	1133 / 23 - Novobiocin-mediated polymerase theta inhibition induces cGAS/STING pathway activation and T-cell infiltration in BRCA-associated cancers	Ludwig Harvard	Jeffrey Patterson-Fortin/Alan D'Andrea, Geoffrey Shapiro.	9:00 AM - 12:30 PM

4/11/22	Session PO.MCB07.01 - Genomic Instability 1	Poster session - Section 5	796 / 5 - Dual inhibition of NHEJ and MMEJ induces synthetic lethality in TP53 mutant cancers	Ludwig Harvard	Jeffrey Patterson-Fortin/Alan D'Andrea	9:00 AM - 12:30 PM
4/11/22	Session PO.CL06.04 - Immune Mechanisms Invoked by Other Therapies	Poster session - Section 32	1288 / 10 - STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer	Ludwig Harvard	Heta Jadhav/Geoffrey I. Shapiro	9:00 AM - 12:30 PM
4/11/22	Session LBPO.TB02 - Late-Breaking Research: Tumor Biology 2	Late breaking poster session - Section 17	LB056 / 8 - The spatial landscape of progression and immunoediting in primary melanoma at single cell resolution	Ludwig Harvard	Ajit Johnson Nirmal/Sandro Santagata, Peter Sorger	9:00 AM - 12:30 PM
4/12/22	Session PO.IM02.03 - Adoptive Cell Therapy 3	Online poster session - Section 35	2822 / 13 - Enhanced effector activity of mediator CDK8 kinase module deficient CAR-T Cells	Ludwig Stanford	Katherine Freitas/Crystal Mackall	9:00 AM - 12:30 PM
4/11/22	Session PO.IM01.02 - Innate Immunity to Cancer	Poster session - Section 40	2100 / 1 - Dendritic cell-intrinsic PTPN22 negatively regulates anti-tumor immunity	Ludwig Chicago	Santiago Acero-Bedoya/Thomas Gajewski	1:30 PM - 5:00 PM
4/11/22	Session PO.TB01.05 - Cell Line and Animal Models	Poster session - Section 11	1618 / 10 - OP-1250 prevents tumor spread in a model of metastatic mutant ER α breast cancer	Ludwig Chicago	Muriel Laine/Geoffrey Greene	1:30 PM - 5:00 PM
4/11/22	SESSION PO.TB10.01 - Causes and Consequences of Tumor Heterogeneity	Poster session - Section 10	1587 / 2 - Multi region single cell sequencing reveals dedifferentiation programs, angiogenic heterogeneity and the effect of microenvironmental hypoxia in ccRCC tumors	Ludwig Oxford	Olivia Lombardi/Peter Ratcliffe and David Mole	1:30 PM - 5:00 PM
4/11/22	Session LBPO.IM01 - Late-Breaking Research: Immunology 1	Late breaking poster session - Section 18	LB098 / 5 - Integrative approaches to modulate antigen presentation and boost cancer immune response	Ludwig Harvard	Shengqing Gu/Myles Brown	1:30 PM - 5:00 PM
4/11/22	Session PO.MCB04.01 - Chromatin, Enhancers, Promoters, and Regulation of Transcription Factor Function	Poster session - Section 3	1470 / 14 - Characterization of ER receptor transcription complex using super resolution STORM microscopy	Ludwig Harvard	Tara Akhshi/Myles Brown	1:30 PM - 5:00 PM
4/12/22	Session LBPO.MCB02 - Late-Breaking Research: Molecular/Cellular Biology and Genetics 2	Late breaking poster session - Section 18	LB134 / 10 - Type 1 calreticulin mutations differentially activate the IRE1 α -XBP1 pathway of the unfolded protein response to drive myeloproliferative neoplasms	Ludwig Chicago	Juan Ibarra/Shannon Elf	9:00 AM - 12:30 PM
4/12/22	Session LBPO.CL02 - Late-Breaking Research: Clinical Research 2	Late breaking poster session - section 17	LB119 / 13 - Precision combination therapies based on recurrent oncogenic co-alterations	Ludwig Harvard	Anil Korkut/Chris Sander	9:00 AM - 12:30 PM
4/12/22	Session PO.CT01.03 - Phase I Trials in Progress 1	Poster session - Section 34	CT201 / 1 - Ceralasertib and olaparib in the treatment of homologous recombination repair (HRR)-deficient platinum-sensitive ovarian cancer after progression on PARP inhibitors	Ludwig Harvard	Geoffrey Shapiro	9:00 AM - 12:30 PM
4/12/22	Session PO.ET06.03 - Novel Targets and Pathways	Poster session - Section 24	2638 / 7 - Sacituzumab Govitecan, combination with PARP inhibitor, Talazoparib, in metastatic triple-negative breast cancer (TNBC): Translational investigation	Ludwig Harvard	Aditya Bardia/Leif Ellisen	9:00 AM - 12:30 PM
4/12/22	Session PO.IM02.19 - Modifiers of the Tumor Microenvironment	Poster session - Section 39	3537 / 7 - Pharmacologic inhibition of the glycolytic pathway improves response to immune checkpoint blockade	Ludwig MSK	Svena Verma/Roberta Zappasodi, Taha Merghoub, Jedd Wolchok	1:30 PM - 5:00 PM
4/13/22	Session PO.MCB05.04 - Chromatin Modifiers: Mutations and Novel Therapeutics	Poster session - Section 6	3720 / 4 - TACH101, a first-in-class inhibitor of KDM4 histone lysine demethylase for the treatment of diffuse large B-cell lymphoma	Ludwig Stanford	Frank Perabo/Michael Clarke	9:00 AM - 12:30 PM
4/13/22	Session PO.MCB05.03 - Epigenomics to Molecular Markers	Poster session - Section 8	3766 / 18 - Correlating locus-specific changes in histone trimethylation and gene expression in hypoxia	Ludwig Oxford	Jessica Kindrick/Peter Ratcliffe and David Mole	9:00 AM - 12:30 PM
4/13/22	Session PO.IM02.05 - Combination Immunotherapies 1	Poster session - Section 36	4167 / 3 - Combination of cyclophosphamide with immune checkpoint blockade inhibition elicits potent tumor control in a preclinical melanoma model	Ludwig MSK	Mariam George/Jedd Wolchok, Taha Merghoub	9:00 AM - 12:30 PM
4/13/22	Session PO.IM02.05 - Combination Immunotherapies 1	Poster session - Section 36	4174 / 10 - Augmenting NK cell based immunotherapy by targeting mitochondrial apoptosis	Ludwig Harvard	Rongqing Aaron Pan/Anthony Letai	9:00 AM - 12:30 PM
4/13/22	Session PO.MCB02.02 - Apoptosis	Poster session - Section 5	3691 / 2 - Dynamic BH3 profiling identifies novel combinations in malignant pleural mesothelioma with in vivo efficacy	Ludwig Harvard	Ruochen Du/Anthony Letai	9:00 AM - 12:30 PM
4/13/22	Session PO.IM02.05 - Combination Immunotherapies 1	Poster session - Section 36	4190 / 26 - Combining dual CAR iPSC-derived immune cells with antibody for multi-antigen targeting to overcome clonal resistance in multiple myeloma	Ludwig Harvard	John Reiser/Kai Wucherpfennig	9:00 AM - 12:30 PM